Drugs for Psoriasis

On this page

Psoriasis: Basics & Goals - Skin Deep Strategy

  • Chronic, immune-mediated inflammatory skin disease; T-cell driven, ↑keratinocyte proliferation.
  • Presents as well-demarcated erythematous plaques with silvery scales.
  • Key cytokines: TNF-α, IL-23, IL-17.
  • Common types: Plaque (vulgaris), guttate, pustular, erythrodermic.
  • Severity: Body Surface Area (BSA), PASI score.
  • Treatment Goals: ↓lesions, ↑Quality of Life, manage comorbidities (psoriatic arthritis), induce remission, minimize drug toxicity. Chronic plaque psoriasis with erythematous plaques

⭐ Auspitz sign: pinpoint bleeding observed upon removal of psoriatic scales.

Topical Therapies - Skin's First Aid

First-line for mild-moderate psoriasis. Treatment Options for Psoriasis

AgentMOA (Simplified)Key ADRsNotes
CorticosteroidsAnti-inflammatory, Anti-proliferativeSkin atrophy, TachyphylaxisPotency varies (mild to superpotent)
Vit D3 Analogs (Calcipotriol)Inhibit keratinocyte proliferationSkin irritation, Hypercalcemia (rare)Good for long-term use, often combined
Retinoids (Tazarotene)Normalize gene expressionIrritation, Photosensitivity⚠️ Teratogenic (Pregnancy CI)
Calcineurin Inhibitors (Tacrolimus, Pimecrolimus)ImmunomodulatoryBurning, Stinging; malignancy risk?Off-label; face/intertriginous areas

Systemic Non-Biologics - Core Systemic Squad

Key systemic agents for moderate-to-severe psoriasis, often used when topical therapy fails or for widespread disease. Systemic non-biologic drugs for psoriasis comparison

DrugMOA (Abbrev.)Key ADRsKey MonitoringCIs (Abbrev.)
MethotrexateDHFR inhib.Hepatotox, myelosupp, mucositisLFTs, CBCPreg, liver dis.
CyclosporineCalcineurin inhNephrotox, HTN, neurotoxBP, renal funcUnctrl HTN, renal imp
AcitretinRetinoidTeratogenic, hyperlipidemia, drynessLFTs, lipidsPreg (3 yrs post)
ApremilastPDE4 inhib.Diarrhea, nausea, headache, depressionWeight, mood-

⭐ Folic acid (1-5 mg daily, or 5 mg weekly) reduces Methotrexate's hematologic, GI, and hepatic side effects.

Biologic Agents - Targeted Skin Warriors

Advanced therapy for moderate-to-severe chronic plaque psoriasis, targeting key cytokines in its pathogenesis.

  • TNF-α Inhibitors: E.g., Infliximab, Adalimumab, Etanercept. Broad immunosuppression, monitor for infections.
  • IL-17 Inhibitors: E.g., Secukinumab, Ixekizumab. Target IL-17A, a key pro-inflammatory cytokine. Rapid efficacy.
  • IL-12/23 Inhibitors: E.g., Ustekinumab. Targets p40 subunit common to both IL-12 & IL-23.
  • IL-23p19 Inhibitors: E.g., Guselkumab, Risankizumab. Highly selective for the IL-23 pathway. ⚠️ Pre-treatment screening for TB is mandatory.

⭐ IL-17 inhibitors like Secukinumab and Ixekizumab are known for their rapid onset of action in clearing psoriatic lesions.

Phototherapy - Healing Light Rays

  • UV light for moderate-to-severe psoriasis.
  • UVB Therapy:
    • NB-UVB: 311-313 nm, preferred. Reduces proliferation, immunomodulates.
  • PUVA (Psoralen + UVA):
    • Oral/topical psoralen + UVA.
    • Inhibits DNA synthesis. Potent for thick plaques; higher risks.
  • SE: Burns, photoaging, ↑ skin cancer risk (PUVA > UVB).

⭐ NB-UVB is often first-line due to better efficacy/safety than PUVA.

High‑Yield Points - ⚡ Biggest Takeaways

  • Topical corticosteroids & Vitamin D analogs (calcipotriol) are primary for mild-moderate psoriasis.
  • Methotrexate, a systemic DMARD, requires LFT monitoring & folic acid; risk of hepatotoxicity.
  • Cyclosporine, potent for severe psoriasis, causes nephrotoxicity; monitor renal function.
  • Acitretin (oral retinoid) is highly teratogenic; contraindicated in pregnancy.
  • Biologics (TNF-α, IL-17, IL-23 inhibitors) treat moderate-severe, refractory psoriasis.
  • Apremilast, an oral PDE4 inhibitor, is a non-biologic systemic option.

Practice Questions: Drugs for Psoriasis

Test your understanding with these related questions

What is the primary condition for which calcitriol is used as a treatment?

1 of 5

Flashcards: Drugs for Psoriasis

1/8

_____ is a monoclonal antibody directed against the p19 subunit of IL-23

TAP TO REVEAL ANSWER

_____ is a monoclonal antibody directed against the p19 subunit of IL-23

Tildrakizumab

browseSpaceflip

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

Start Your Free Trial